10 Questions You Should be Asking About Your Rx Benefits Plan: Part 2

January 9, 2020

Welcome to part two of our blog series 10 Questions You Should be Asking About Your Rx Benefits Plan!

If you missed part one in last week’s blog, be sure to check it out here.

Last week we discussed the various PBM models and how pricing strategies can impact your plan spend. Now, let’s dig a little deeper into PBM contracts and look at definitions, rebate caveats and PBM revenue streams.

Plan sponsors should consider the following aspects of your PBM contract:

HOW ARE BRANDS AND GENERICS DEFINED IN YOUR PBM CONTRACT, AND ARE THESE DEFINITIONS CONSISTENT THROUGHOUT THE CONTRACT?

Review your contract for any changes in language regarding how drugs are defined or bucketed for guarantee purposes. Contract loopholes enable the PBM to shift commonly used generic drugs into the PBM’s calculation of its brand drug contract guarantees. This makes it easy to satisfy the guarantees and allows for PBMs to generate hidden revenue. It can also inflate the perceived cost savings if not applied to the appropriate claim set, for both network costs and rebates paid. 

ARE THERE REBATE CAVEATS, AND HOW DOES THIS IMPACT THE REBATE VALUE YOU RECEIVE?

Caveats can create optics that make the rebate appear higher on a spreadsheet than what you ultimately receive. Look for any rebate guarantee contingencies, including, but not limited to:

  • Tiered design
  • Minimum copay
  • Minimum coinsurance
  • Required step therapy programs
  • Highly exclusionary formulary
  • Retail 30 based upon a 1-83 day supply
  • Retail 90 based upon a 84-90 day supply

Do you know which claims are excluded? The list can be extensive and negatively impact the value you will receive. To level set, ask for the number of brand claims, total dollars by channel and average days’ supply. Make sure exclusions are the same across all PBMs.

ARE YOU RECEIVING 100% OF ALL THE REVENUE YOUR PBM RECEIVES FROM PHARMA?

Ask for number of brand claims, total dollars by channel and average days’ supply. Find out if any rebate aggregators or rebate intermediaries are involved. Make sure any improvement to rebate contracts during your contract term are immediately passed back to you.

PBMs may receive pharma revenues in various forms, including:

  • Formulary rebates
  • Administrative fees
  • Market share fees
  • Health management fees
  • Data sales fees
  • Educational fees
  • Purchase discounts

WHAT IS INCLUDED IN YOUR ADMINISTRATIVE FEE?

A low administrative fee may look good on the bottom line, but what are you giving up that you may be unaware of? Administrative fees should not be tied to claims activity, including denied and reversed claims, as this practice often results in encouraging increased claims activity, which leads to a higher drug spend. Instead, the admin fee should be based on your total membership.

Learn more about PBM contract types, definitions and pricing practices in our ebook, 7 Things You Need to Know About Pharmacy Benefit Management (PBM) Models.

Download the E-book

Be on the lookout for the final installment of this three-part blog series next week!

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Examining Trends that Drive Informed Decisions

Now Available: 8th Annual Drug Trend Report

See the latest results and access industry insights you need to navigate current trend drivers.

Related blogs

Navigating Healthcare and Improving Outcomes

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

In this overview of our national Legal Ease webinar event, we highlight key federal and state developments shaping the conversation around PBM reform – and what they mean for your clients.  …

Navigating the Drug Supply Chain: What You Need to Know

Navigating the Drug Supply Chain: What You Need to Know

Before a prescription ever reaches a pharmacy counter, it has already moved through a complex ecosystem known as the drug supply chain. From manufacturers and wholesalers to pharmacy benefit managers (PBMs) and pharmacies, each entity plays a role in…

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…

PBM 101: Why the Model Matters

PBM 101: Why the Model Matters

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…

Associate Resource Group Spotlight: Green Team

Associate Resource Group Spotlight: Green Team

The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….

PBM 101: The Three PBM Business Models

PBM 101: The Three PBM Business Models

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

previous arrow
next arrow